Søgeord (covid-19) valgt.
628 emner vises.
1
Anxiety, Depression Soared in Young Adults During Pandemic
Medscape Infectious Diseases, 8.12.2023
Tilføjet 8.12.2023
More than a third of young adults living in the US during the COVID-19 pandemic experienced anxiety and/or depression, an outcome that may be related to economic or social uncertainty. Medscape Medical News
Læs mere
2
Factors associated with parental intention to vaccinate their child against influenza, Finland, February to March, 2022: a web-based survey
Idil Hussein, Simopekka Vänskä, Jonas Sivelä, Tuija Leino and Hanna Nohynek
Eurosurveillance latest updates, 8.12.2023
Tilføjet 8.12.2023
BackgroundInfluenza vaccination for children aged 6 months to 6 years is included in the national vaccination programme in Finland. Although all vaccines in the programme are free of charge, national coverage of influenza vaccination among children under 3 years and 3–6 years during 2020/21 was 43% and 35% respectively, with regional differences. AimTo assess factors underlying parental vaccination intention in order to increase influenza vaccine uptake among children. MethodsWe conducted a web-based survey among parents (n = 17,844) of randomly selected eligible children (aged 6 months–6 years) in February–March 2022 in five Finnish municipalities from regions of high and low coverage. Logistic regressions were used to determine associations between vaccination intention and e.g. sociodemographic factors, attitudes and knowledge. Linkage to the national vaccination register was used to confirm realisation of vaccination intention after the study. ResultsParticipation rate was 13% (n = 2,322 parents). Influenza knowledge, trust in official information, responding parent’s education level, adherence to the vaccination programme, number of children and changes in attitudes towards vaccination since COVID-19 were all associated with intention to vaccinate. Vaccination intention for children was 64%, and realised vaccination 51%. ConclusionDespite the low participation rate, both vaccinated and unvaccinated children were represented. Influenza vaccine uptake is not dependent on a single factor. Our results identified the need for open dialogue between parents and healthcare professionals, as the lack of vaccine being offered by healthcare professionals was the most reported reason for not vaccinating.
Læs mere
3
COVID, Flu Rates Rising Nationwide, but RSV May Have Peaked
Medscape Infectious Diseases, 6.12.2023
Tilføjet 6.12.2023
COVID-19 appears to be heading for a holiday season increase across most of the United States. WebMD Health News
Læs mere
4
COVID Vaccines Lower Risk of Serious Illness in Kids
Medscape Infectious Diseases, 1.12.2023
Tilføjet 1.12.2023
Two doses of an mRNA COVID-19 vaccine reduced hospitalizations and emergency department visits by 40%. Medscape Medical News
Læs mere
5
Relative vaccine effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter (bivalent vaccine) booster campaigns: a prospective test negative case–control study, United Kingdom, 2022
Anastasia Chatzilena, Catherine Hyams, Rob Challen, Robin Marlow, Jade King, David Adegbite, Jane Kinney, Madeleine Clout, Nick Maskell, Jennifer Oliver, Adam Finn, Leon Danon and on behalf of The Avon CAP Research Group
Eurosurveillance latest updates, 1.12.2023
Tilføjet 1.12.2023
BackgroundUnderstanding the relative vaccine effectiveness (rVE) of new COVID-19 vaccine formulations against SARS-CoV-2 infection is a public health priority. A precise analysis of the rVE of monovalent and bivalent boosters given during the 2022 spring-summer and autumn-winter campaigns, respectively, in a defined population remains of interest. AimWe assessed rVE against hospitalisation for the spring-summer (fourth vs third monovalent mRNA vaccine doses) and autumn-winter (fifth BA.1/ancestral bivalent vs fourth monovalent mRNA vaccine dose) boosters. MethodsWe performed a prospective single-centre test-negative design case–control study in ≥ 75-year-old people hospitalised with COVID-19 or other acute respiratory disease. We conducted regression analyses controlling for age, sex, socioeconomic status, patient comorbidities, community SARS-CoV-2 prevalence, vaccine brand and time between baseline dose and hospitalisation. ResultsWe included 682 controls and 182 cases in the spring-summer booster analysis and 572 controls and 152 cases in the autumn-winter booster analysis. A monovalent mRNA COVID-19 vaccine as fourth dose showed 46.6% rVE (95% confidence interval (CI): 13.9–67.1) vs those not fully boosted. A bivalent mRNA COVID-19 vaccine as fifth dose had 46.7% rVE (95% CI: 18.0–65.1), compared with a fourth monovalent mRNA COVID-19 vaccine dose. ConclusionsBoth fourth monovalent and fifth BA.1/ancestral mRNA bivalent COVID-19 vaccine doses demonstrated benefit as a booster in older adults. Bivalent mRNA boosters offered similar protection against hospitalisation with Omicron infection to monovalent mRNA boosters given earlier in the year. These findings support immunisation programmes in several European countries that advised the use of BA.1/ancestral bivalent booster doses.
Læs mere
6
SARS-CoV-2 Epidemiology and COVID-19 mRNA Vaccine Effectiveness Among Infants and Children Aged 6 Months-4 Years - New Vaccine Surveillance Network, United States, July 2022-September 2023
Morbidity and Mortality Weekly Report (MMWR), 1.12.2023
Tilføjet 1.12.2023
This report describes the effectiveness of COVID-19 mRNA vaccines among infants and children aged 6 months-4 years.
Læs mere
7
Interim analysis of COVID-19 vaccine effectiveness against hospitalisation and death using electronic health records in six European countries
ECDC
ECDC COVID-19 updates, 30.11.2023
Tilføjet 30.11.2023
This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses, against hospitalisation due to COVID-19 and COVID-19 related deaths in resident populations ≥50 years of age, living in the community.
Læs mere
8
COVID Vax T-Cell Responses Help B-Cell–Deficient Patients
Medscape Infectious Diseases, 30.11.2023
Tilføjet 30.11.2023
The findings demonstrate how vaccine-induced T-cell responses could potentially reduce COVID-19 severity, the authors write. Medscape Medical News
Læs mere
9
New CDC Advisory Once Again Flags BA.2.86 COVID Variant
Medscape Infectious Diseases, 30.11.2023
Tilføjet 30.11.2023
An emerging variant of COVID-19 called BA.2.86 that caused alarm earlier this summer has landed on the CDC\'s radar again. WebMD Health News
Læs mere
10
Reporting Protocol for integrated respiratory virus surveillance, version 1.3
ECDC
ECDC COVID-19 updates, 28.11.2023
Tilføjet 28.11.2023
This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.
Læs mere
11
Pandemic Tied to a 50% Drop in Memory, Executive Function
Medscape Infectious Diseases, 27.11.2023
Tilføjet 27.11.2023
The first year of the COVID-19 pandemic is associated with a 50% decline in working memory and executive function among older adults, a new UK study suggests. Medscape Medical News
Læs mere
12
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021
Angela MC Rose, Nathalie Nicolay, Virginia Sandonis Martín, Clara Mazagatos, Goranka Petrović, F Annabel Niessen, Ausenda Machado, Odile Launay, Sarah Denayer, Lucie Seyler, Joaquin Baruch, Cristina Burgui, Isabela I Loghin, Lisa Domegan, Roberta Vaikutytė, Petr Husa, George Panagiotakopoulos, Nassera Aouali, Ralf Dürrwald, Jennifer Howard, Francisco Pozo, Bartolomé Sastre-Palou, Diana Nonković, Mirjam J Knol, Irina Kislaya, Liem binh Luong Nguyen, Nathalie Bossuyt, Thomas Demuyser, Aušra Džiugytė, Iván Martínez-Baz, Corneliu Popescu, Róisín Duffy, Monika Kuliešė, Lenka Součková, Stella Michelaki, Marc Simon, Janine Reiche, María Teresa Otero-Barrós, Zvjezdana Lovrić Makarić, Patricia CJL Bruijning-Verhagen, Verónica Gomez, Zineb Lesieur, Cyril Barbezange, Els Van Nedervelde, Maria-Louise Borg, Jesús Castilla, Mihaela Lazar, Joan O’Donnell, Indrė Jonikaitė, Regina Demlová, Marina Amerali, Gil Wirtz, Kristin Tolksdorf, Marta Valenciano, Sabrina Bacci, Esther Kissling, I-MOVE-COVID-19 hospital study team and VEBIS hospital study team
Eurosurveillance latest updates, 24.11.2023
Tilføjet 24.11.2023
IntroductionTwo large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021. AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March–June)- and Delta (June–December)-dominant periods, 2021. MethodsForty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case–control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine ≥ 14 days before onset. ResultsWe included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69–92) overall and 75% (95% CI: 42–90) in those aged ≥ 80 years. During the Delta period, among SARI patients ≥ 20 years with symptom onset ≥ 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18–74). Among those receiving Comirnaty PSV and mRNA booster (any product) ≥ 150 days after last PSV dose, VE was 91% (95% CI: 57–98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose
Læs mere
13
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022
Angela MC Rose, Nathalie Nicolay, Virginia Sandonis Martín, Clara Mazagatos, Goranka Petrović, Joaquin Baruch, Sarah Denayer, Lucie Seyler, Lisa Domegan, Odile Launay, Ausenda Machado, Cristina Burgui, Roberta Vaikutyte, F Annabel Niessen, Isabela I Loghin, Petr Husa, Nassera Aouali, George Panagiotakopoulos, Kristin Tolksdorf, Judit Krisztina Horváth, Jennifer Howard, Francisco Pozo, Virtudes Gallardo, Diana Nonković, Aušra Džiugytė, Nathalie Bossuyt, Thomas Demuyser, Róisín Duffy, Liem binh Luong Nguyen, Irina Kislaya, Iván Martínez-Baz, Giedre Gefenaite, Mirjam J Knol, Corneliu Popescu, Lenka Součková, Marc Simon, Stella Michelaki, Janine Reiche, Annamária Ferenczi, Concepción Delgado-Sanz, Zvjezdana Lovrić Makarić, John Paul Cauchi, Cyril Barbezange, Els Van Nedervelde, Joan O’Donnell, Christine Durier, Raquel Guiomar, Jesús Castilla, Indrė Jonikaite, Patricia CJL Bruijning-Verhagen, Mihaela Lazar, Regina Demlová, Gil Wirtz, Marina Amerali, Ralf Dürrwald, Mihály Pál Kunstár, Esther Kissling, Sabrina Bacci, Marta Valenciano, I-MOVE-COVID-19 hospital study team and VEBIS hospital study team
Eurosurveillance latest updates, 24.11.2023
Tilføjet 24.11.2023
IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). MethodsIn both networks, 46 hospitals (13 countries) follow a similar test-negative case–control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received
Læs mere
14
Effectiveness of bivalent COVID-19 boosters against COVID-19 mortality in people aged 65 years and older, Australia, November 2022 to May 2023
Bette Liu, Sandrine Stepien, Ketaki Sharma and Kristine Macartney
Eurosurveillance latest updates, 24.11.2023
Tilføjet 24.11.2023
We followed 4,081,257 Australian adults aged ≥ 65 years between November 2022 and May 2023 for COVID-19-specific mortality, when recombinant SARS-CoV-2 Omicron lineages (predominantly XB and XBB) as well as BA.2.75 were circulating. Compared with a COVID-19 booster targeting ancestral SARS-CoV-2 given > 180 days earlier, the relative vaccine effectiveness against COVID-19 death of a bivalent (ancestral/BA.1 or ancestral/BA.4-5) booster given 8 to 90 days earlier was 66.0% (95%CI: 57.6 to 72.2%) and that of a monovalent ancestral booster given 8 to 90 days earlier was 44.7% (95%CI: 23.9 to 59.7%).
Læs mere
15
Notes from the Field: Diagnosis of Congenital Syphilis and Syphilis Among Females of Reproductive Age Before and During the COVID-19 Pandemic - Chicago, 2015-2022
Morbidity and Mortality Weekly Report (MMWR), 23.11.2023
Tilføjet 23.11.2023
This report describes increases in cases of congenital syphilis during the COVID-19 pandemic.
Læs mere
16
Early detection of the emerging SARS-CoV-2 BA.2.86 lineage through integrated genomic surveillance of wastewater and COVID-19 cases in Sweden, weeks 31 to 38 2023
Carmen Espinosa-Gongora, Carlo Berg, Moa Rehn, Javier Edo Varg, Lena Dillner, Neus Latorre-Margalef, Anna J Székely, Emmi Andersson and Elin Movert
Eurosurveillance latest updates, 17.11.2023
Tilføjet 17.11.2023
The SARS-CoV-2 BA.2.86 Omicron subvariant was first detected in wastewater in Sweden in week 31 2023, using 21 highly specific markers from the 50 investigated. We report BA.2.86’s introduction and subsequent spread to all 14 regions performing wastewater sampling, and on 70 confirmed COVID-19 cases, along with the emergence of sublineages JN.1 and JN.2. Further, we investigated two novel mutations defining the unique BA.2.86 branching in Sweden. Our integrated approach enabled variant tracking, offering evidence for well-informed public health interventions.
Læs mere
17
Rebound in community antibiotic consumption after the observed decrease during the COVID-19 pandemic, EU/EEA, 2022
Cèlia Ventura-Gabarró, Vivian H Leung, Vera Vlahović-Palčevski, Anna Machowska, Dominique L Monnet, Liselotte Diaz Högberg and ESAC-Net study group
Eurosurveillance latest updates, 17.11.2023
Tilføjet 17.11.2023
We observed a rebound in consumption of antibacterials for systemic use (ATC J01) in the community sector in the European Union/European Economic Area during 2021 and 2022, after an observed decrease between 2019 and 2020. The rates in 2022 returned to pre-COVID-19-pandemic levels and were exceeded in 13 countries. Although these patterns could partly be a result of changes in disease transmission during the study period, it could also reflect a lost opportunity to strengthen and reinforce prudent antibiotic use.
Læs mere
18
Efterårets covid-19-vacciner reducerer risikoen for indlæggelse med 75 procent
Statens Serum Institut, 16.11.2023
Tilføjet 16.11.2023
De variantopdaterede covid-19-vacciner, som er rettet mod nyere varianter af coronavirus, og som er blevet givet siden oktober i år, giver god beskyttelse mod alvorlig sygdom.
Læs mere
19
COVID-19 Antivirals Can Trigger Viral Rebound
Medscape Infectious Diseases, 14.11.2023
Tilføjet 14.11.2023
Though antivirals are critical for reducing severe COVID-19 symptoms, researchers suggested that the medication may not always be needed for milder cases. Medscape Medical News
Læs mere
20
Pandemic Tied to a 50% Drop in Memory, Executive Function
Medscape Infectious Diseases, 13.11.2023
Tilføjet 13.11.2023
A 50% decline in working memory and executive function among older adults in the United Kingdom during the first year of the COVID-19 pandemic is linked to an increase in known risk factors for dementia. Medscape Medical News
Læs mere
21
Declines in Influenza Vaccination Coverage Among Health Care Personnel in Acute Care Hospitals During the COVID-19 Pandemic - United States, 2017-2023
Morbidity and Mortality Weekly Report (MMWR), 9.11.2023
Tilføjet 9.11.2023
This report describes declines in influenza vaccination coverage among health care personnel working in hospitals during the COVID-19 pandemic.
Læs mere
22
Influenza and Up-to-Date COVID-19 Vaccination Coverage Among Health Care Personnel - National Healthcare Safety Network, United States, 2022-23 Influenza Season
Morbidity and Mortality Weekly Report (MMWR), 9.11.2023
Tilføjet 9.11.2023
This report describes the percentage of health care personnel working in hospitals and nursing homes who received a flu vaccine and the percentage who received a COVID-19 vaccine.
Læs mere
23
PCR testing of traced contacts for SARS-CoV-2 in England, January to July 2021
Toby Nonnenmacher, Niharika Dandamudi, Matthias Erwin Futschik, Sarah A Tunkel, Raghavendran Kulasegaran-Shylini, Nick Germanacos, Joanna Cole-Hamilton, Edward Blandford, Ashley Goddard, Joe Hillier, Stephen Finer, Susan Hopkins and Tom Fowler
Eurosurveillance latest updates, 3.11.2023
Tilføjet 3.11.2023
BackgroundThe NHS Test and Trace (NHSTT) programme was established in May 2020 in England to deliver SARS-CoV-2 testing and contact tracing in order to identify infected individuals and reduce COVID-19 spread. To further control transmission, people identified as contacts were asked to self-isolate for 10 days and test only if they became symptomatic. From March 2021, eligibility criteria for PCR testing expanded to include asymptomatic contacts of confirmed cases. AimTo analyse testing patterns of contacts before and after the change in testing guidance in England to assess the impact on PCR testing behaviour with respect to symptom status and contact type. MethodsTesting and contact tracing data were extracted from the national data systems and linked. Subsequently, descriptive statistical analysis was applied to identify trends in testing behaviour. ResultsBetween 1 January and 31 July 2021, over 5 million contacts were identified and reached by contact tracers; 42.3% took a PCR test around the time they were traced. Overall positivity rate was 44.3% and consistently higher in symptomatic (60–70%) than asymptomatic (around 20%, March–June) contacts. The proportion of tests taken by asymptomatic contacts increased over time, especially after the change in testing guidance. No link was observed between uptake of PCR tests and vaccination coverage. Fully vaccinated contacts showed lower positivity (23.8%) than those with one dose (37.2%) or unvaccinated (51.0%). ConclusionAlmost 1 million asymptomatic contacts were tested for SARS-CoV-2, identifying 214,056 positive cases, demonstrating the value of offering PCR testing to this group.
Læs mere
24
No Increase in MS Disease Activity Due to COVID-19
Medscape Infectious Diseases, 3.11.2023
Tilføjet 3.11.2023
COVID-19 has no impact on disease activity, progression, or cognitive performance in patients with multiple sclerosis. Medscape Medical News
Læs mere
25
Elderly Patients at Highest Risk for Severe COVID Outcomes
Medscape Infectious Diseases, 3.11.2023
Tilføjet 3.11.2023
Among Canadians, patients aged 80 years or older are the least likely to have a history of COVID-19 infection and the most likely to be hospitalized or die following infection, data indicate. Medscape Medical News
Læs mere
26
Paxlovid Doesn't Reduce Most Post-COVID Conditions
Medscape Infectious Diseases, 31.10.2023
Tilføjet 31.10.2023
With the exception of venous thromboembolism and pulmonary embolism events, the antiviral drug did not reduce the incidence of post-COVID-19 conditions in a study of nearly 10,000 US veterans. Medscape Medical News
Læs mere
27
How to Boost COVID Vaccination Rates in Pregnant Women
Medscape Infectious Diseases, 31.10.2023
Tilføjet 31.10.2023
Physicians provided tips on how to increase rates of pregnant women receiving the COVID-19 booster. Medscape Medical News
Læs mere
28
Reporting Protocol for integrated respiratory virus surveillance v1.1
ECDC
ECDC COVID-19 updates, 30.10.2023
Tilføjet 30.10.2023
This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.
Læs mere
29
Endoscopic Features of Post-COVID Cholangiopathy Defined
Medscape Infectious Diseases, 27.10.2023
Tilføjet 27.10.2023
Researchers report endoscopic features and propose diagnostic criteria for post–COVID-19 cholangiopathy — one of the most serious long-term gastrointestinal consequences of COVID-19. Medscape Medical News
Læs mere
30
Notes from the Field: Early Identification of the SARS-CoV-2 Omicron BA.2.86 Variant by the Traveler-Based Genomic Surveillance Program - Dulles International Airport, August 2023
Morbidity and Mortality Weekly Report (MMWR), 26.10.2023
Tilføjet 26.10.2023
CDC detected BA.2.86 variant in a traveler within days of being reported. Timely detection provides early warning of new COVID-19 variants entering the U.S.
Læs mere
31
mRNA Vaccine Cuts COVID-Related Guillain-Barré Risk
Medscape Infectious Diseases, 26.10.2023
Tilføjet 26.10.2023
COVID-19 increases the risk for Guillain-Barré syndrome sixfold, while getting the Pfizer mRNA vaccine lowers risk. Medscape Medical News
Læs mere
32
Der er stigning i smitten af flere luftvejssygdomme nu
Statens Serum Institut, 26.10.2023
Tilføjet 26.10.2023
Både forekomsten af RS-virus, covid-19 og kighoste er i stigning. Sæsonen for RS-virus er nu startet, mens kighoste-forekomsten fortsætter på et epidemisk højt niveau, og forekomsten af covid-19 er støt stigende. Det viser den integrerede overvågning fra Statens Serum Institut (SSI).
Læs mere
33
Vax Status Doesn't Impact Infectivity Timeline in Kids
Medscape Infectious Diseases, 24.10.2023
Tilføjet 24.10.2023
Roughly half of children are noninfectious 3 days after a positive COVID-19 test, independent of vaccination status. Medscape Medical News
Læs mere
34
Evidence-based advice processes for long-term care facilities in the COVID-19 pandemic - Aggregate report from the After-Action reviews in Georgia and Norway
ECDC
ECDC COVID-19 updates, 19.10.2023
Tilføjet 19.10.2023
This report is based on the findings from two focused After-Action reviews (AARs) in Norway and Georgia that discussed the use of evidence in the advice-making process for long-term care facilities (LTCFs) during the start of the COVID-19 Omicron wave in early 2022.
Læs mere
35
Evidence-based advice processes for long-term care facilities in the COVID-19 pandemic - Report from the after-action review (AAR) in Norway
ECDC
ECDC COVID-19 updates, 17.10.2023
Tilføjet 17.10.2023
Report from the after-action review (AAR) in Norway during the emergence of the Omicron variant of concern of SARS-CoV-2.
Læs mere
36
Communicable disease threats report, 8-14 October 2023, week 41
ECDC
ECDC Communicable Disease Threats Report, 13.10.2023
Tilføjet 13.10.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 8-14 October 2023 and includes updates on hepatitis A, influenza A(H5N1), COVID-19, the Rugby World Cup 2023, West Nile virus, measles and diphtheria.
Læs mere
37
Communicable disease threats report, 8-14 October 2023, week 41
ECDC
ECDC COVID-19 updates, 13.10.2023
Tilføjet 13.10.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 8-14 October 2023 and includes updates on hepatitis A, influenza A(H5N1), COVID-19, the Rugby World Cup 2023, West Nile virus, measles and diphtheria.
Læs mere
38
The value of manual backward contact tracing to control COVID-19 in practice, the Netherlands, February to March 2021: a pilot study
Timo Louis Boelsums, Inge Anna Theresia van de Luitgaarden, Jane Whelan, Hanna Poell, Charlotte Maria Hoffman, Ewout Fanoy, Maaike Buskermolen and Jan Hendrik Richardus
Eurosurveillance latest updates, 13.10.2023
Tilføjet 13.10.2023
BackgroundContact tracing has been a key component of COVID-19 outbreak control. Backward contact tracing (BCT) aims to trace the source that infected the index case and, thereafter, the cases infected by the source. Modelling studies have suggested BCT will substantially reduce SARS-CoV-2 transmission in addition to forward contact tracing. AimTo assess the feasibility and impact of adding BCT in practice. MethodsWe identified COVID-19 cases who were already registered in the electronic database between 19 February and 10 March 2021 for routine contact tracing at the Public Health Service (PHS) of Rotterdam-Rijnmond, the Netherlands (pop. 1.3 million). We investigated if, through a structured questionnaire by dedicated contact tracers, we could trace additional sources and cases infected by these sources. Potential sources identified by the index were approached to trace the source’s contacts. We evaluated the number of source contacts that could be additionally quarantined. ResultsOf 7,448 COVID-19 cases interviewed in the study period, 47% (n = 3,497) indicated a source that was already registered as a case in the PHS electronic database. A potential, not yet registered source was traced in 13% (n = 979). Backward contact tracing was possible in 62 of 979 cases, from whom an additional 133 potential sources were traced, and four were eligible for tracing of source contacts. Two additional contacts traced had to stay in quarantine for 1 day. No new COVID-19 cases were confirmed. ConclusionsThe addition of manual BCT to control the COVID-19 pandemic did not provide added value in our study setting.
Læs mere
39
Epidemiology of common infectious diseases before and during the COVID-19 pandemic in Bavaria, Germany, 2016 to 2021: an analysis of routine surveillance data
Sarah van de Berg, Tanja Charles, Achim Dörre, Katharina Katz and Stefanie Böhm
Eurosurveillance latest updates, 13.10.2023
Tilføjet 13.10.2023
BackgroundUnprecedented non-pharmaceutical interventions to control the COVID-19 pandemic also had an effect on other infectious diseases. AimWe aimed to determine their impact on transmission and diagnosis of notifiable diseases other than COVID-19 in Bavaria, Germany, in 2020 and 2021. MethodsWe compared weekly cases of 15 notifiable infectious diseases recorded in Bavaria between 1 January 2016 and 31 December 2021 in time series analyses, median age and time-to-diagnosis using Wilcoxon rank sum test and hospitalisation rates using univariable logistic regression during three time periods: pre-pandemic (weeks 1 2016–9 2020), pandemic years 1 (weeks 10–52 2020) and 2 (2021). ResultsWeekly case numbers decreased in pandemic year 1 for all diseases assessed except influenza, Lyme disease and tick-borne encephalitis; markedly for norovirus gastroenteritis (IRR = 0.15; 95% CI: 0.12–0.20) and pertussis (IRR = 0.22; 95% CI: 0.18–0.26). In pandemic year 2, influenza (IRR = 0.04; 95% CI: 0.02–0.09) and pertussis (IRR = 0.11; 95% CI: 0.09–0.14) decreased markedly, but also chickenpox, dengue fever, Haemophilus influenzae invasive infection, hepatitis C, legionellosis, noro- and rotavirus gastroenteritis and salmonellosis. For enterohaemorrhagic Escherichia coli infections, median age decreased in pandemic years 1 and 2 (4 years, interquartile range (IQR): 1–32 and 3 years, IQR: 1–18 vs 11 years, IQR: 2–42); hospitalisation proportions increased in pandemic year 1 (OR = 1.60; 95% CI: 1.08–2.34). ConclusionReductions for various infectious diseases and changes in case characteristics in 2020 and 2021 indicate reduced transmission of notifiable diseases other than COVID-19 due to interventions and under-detection.
Læs mere
40
Implementation of a broad public health approach to COVID-19 in Sweden, January 2020 to May 2022
Anders Tegnell, Anna Bessö, Britta Björkholm, Sara Byfors, Johan Carlson and Karin Tegmark Wisell
Eurosurveillance latest updates, 13.10.2023
Tilføjet 13.10.2023
In 2020, the world had to adapt to a pandemic caused by a then novel coronavirus. In addition to its direct impact on morbidity and mortality, the COVID-19 pandemic brought unprecedented control measures and challenges to both individuals and society. Sweden has been seen by many as an outlier in the management of the pandemic. It is therefore of special interest to document the actual management of the pandemic in Sweden during its first 2 years and how public health was affected. In the authors opinion, within the Swedish context, it has been possible to achieve a similar level of effect on mortality and morbidity through recommendations as was achieved through stringent legal measures in comparable countries. This is supported by comparisons of excess mortality that have been published. Furthermore, we see in the available data that the consequences on mental health and living habits were very limited for the majority of the population. Trust in public institutions is high in Sweden, which has been important and is part of the context that made it possible to manage a pandemic with relatively ‘soft’ measures. We acknowledge challenges in protecting certain vulnerable groups, particularly during the first and second wave.
Læs mere
41
EARLY RELEASE: Use of Updated COVID-19 Vaccines 2023-2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2023
Morbidity and Mortality Weekly Report (MMWR), 11.10.2023
Tilføjet 11.10.2023
This report describes the Advisory Committee on Immunization Practices\' recommendation that all people aged 6 months and older get an updated COVID-19 vaccine.
Læs mere
42
Paxlovid Tied to Benefits in High-Risk Patients With COVID
Medscape Infectious Diseases, 10.10.2023
Tilføjet 10.10.2023
The use of nirmatrelvir–ritonavir (Paxlovid) is associated with a lower risk for death or hospitalization in extremely vulnerable patients with COVID-19. Low-risk patients do not appear to benefit. Medscape Medical News
Læs mere
43
WHO/Europe, EC and ECDC urge eligible groups to get vaccinated or boosted to save lives this autumn and winter
ECDC
ECDC COVID-19 updates, 9.10.2023
Tilføjet 9.10.2023
As autumn moves to winter, the WHO/Europe, EC and ECDC are issuing a clear, urgent message: people who remain unprotected against both COVID-19 and seasonal influenza – especially the most vulnerable and at-risk – should take up any offer for vaccination to prevent or mitigate the impact of these co-circulating respiratory infections.
Læs mere
44
Communicable disease threats report, 1-7 October 2023, week 40
ECDC
ECDC Communicable Disease Threats Report, 6.10.2023
Tilføjet 6.10.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 1 - 7 October 2023 and includes updates on dengue, West Nile virus disease, COVID-19, chikungunya, Middle East respiratory syndrome, mpox, and mass gathering monitoring for the Rugby World Cup.
Læs mere
45
COVID-19 Tied to Autoimmune Disease Risk
Medscape Infectious Diseases, 6.10.2023
Tilføjet 6.10.2023
Patients with more severe COVID-19 that required hospitalization in the ICU were more likely to develop vasculitis, alopecia totalis, and several other autoimmune conditions. Medscape Medical News
Læs mere
46
Communicable disease threats report, 1-7 October 2023, week 40
ECDC
ECDC COVID-19 updates, 6.10.2023
Tilføjet 6.10.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 1 - 7 October 2023 and includes updates on dengue, West Nile virus disease, COVID-19, chikungunya, Middle East respiratory syndrome, mpox, and mass gathering monitoring for the Rugby World Cup.
Læs mere
47
A comparison of COVID-19 incidence rates across six European countries in 2021
Michael Padget, Pauline Adam, Marina Dorfmuller, Clara Blondel, Ines Campos-Matos, Myriam Fayad, Alberto Mateo-Urdiales, David Mesher, Adriana Pistol, Javiera Rebolledo, Flavia Riccardo, Maximilian Riess, Lavinia Cipriana Rusu, Didier Che, Bruno Coignard and COVID-19 Study group
Eurosurveillance latest updates, 6.10.2023
Tilføjet 6.10.2023
International comparisons of COVID-19 incidence rates have helped gain insights into the characteristics of the disease, benchmark disease impact, shape public health measures and inform potential travel restrictions and border control measures. However, these comparisons may be biased by differences in COVID-19 surveillance systems and approaches to reporting in each country. To better understand these differences and their impact on incidence comparisons, we collected data on surveillance systems from six European countries: Belgium, England, France, Italy, Romania and Sweden. Data collected included: target testing populations, access to testing, case definitions, data entry and management and statistical approaches to incidence calculation. Average testing, incidence and contextual data were also collected. Data represented the surveillance systems as they were in mid-May 2021. Overall, important differences between surveillance systems were detected. Results showed wide variations in testing rates, access to free testing and the types of tests recorded in national databases, which may substantially limit incidence comparability. By systematically including testing information when comparing incidence rates, these comparisons may be greatly improved. New indicators incorporating testing or existing indicators such as death or hospitalisation will be important to improving international comparisons.
Læs mere
48
Disparities in COVID-19 Vaccination Status Among Long-Term Care Facility Residents - United States, October 31, 2022-May 7, 2023
Morbidity and Mortality Weekly Report (MMWR), 6.10.2023
Tilføjet 6.10.2023
This report describes COVID-19 vaccination coverage among long-term care facility residents.
Læs mere
49
COVID-19-Associated Hospitalizations Among U.S. Adults Aged ≥65 Years - COVID-NET, 13 States, January-August 2023
Morbidity and Mortality Weekly Report (MMWR), 6.10.2023
Tilføjet 6.10.2023
This report describes COVID-19-associated hospitalizations among older adults.
Læs mere
50
Disease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged ≥60 Years - IVY Network, 20 U.S. States, February 2022-May 2023
Morbidity and Mortality Weekly Report (MMWR), 6.10.2023
Tilføjet 6.10.2023
This report describes the severity of respiratory syncytial virus disease among hospitalized older adults compared to hospitalizations for COVID-19 or influenza.
Læs mere